Received May 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y015355 | OT |
No adverse event; Caller reported PROQUAD administered after temperature excursion. No additional information provided. No additional AE/PQC reported. ? Names of vaccines involved (including lot/exp) PROQUAD Y015355 3/10/2026 ? Temperature -14C; This spontaneous report was received from an Other health professional and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 08-May-2025, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) injection, (lot #Y015355, expiration date: 10-Mar-2026) at a dose of 0.5 mL administered by Subcutaneous route for prophylaxis. It was reported that Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) was administered after temperature excursion of -14 Celsius degrees (C) for the timeframe of 15 minutes (Product storage error). No additional information was provided. No additional AE/PQC was reported (No adverse event).
Sterile diluent